Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2012, Article ID 756291, 16 pages
http://dx.doi.org/10.1155/2012/756291
Review Article

TNF-α Polymorphisms in Juvenile Idiopathic Arthritis: Which Potential Clinical Implications?

Department of Pediatrics, University of Chieti, Via Vestini 5, 66100 Chieti, Italy

Received 20 February 2012; Revised 13 July 2012; Accepted 3 August 2012

Academic Editor: Timothy Radstake

Copyright © 2012 A. Scardapane et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. G. Helmick, D. T. Felson, R. C. Lawrence et al., “Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I,” Arthritis and Rheumatism, vol. 58, no. 1, pp. 15–25, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Martini and D. J. Lovell, “Juvenile idiopathic arthritis: state of the art and future perspectives,” Annals of the Rheumatic Diseases, vol. 69, no. 7, pp. 1260–1263, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Murray, S. D. Thompson, and D. N. Glass, “Pathogenesis of juvenile chronic arthritis: genetic and environmental factors,” Archives of Disease in Childhood, vol. 77, no. 6, pp. 530–534, 1997. View at Google Scholar · View at Scopus
  4. A. Ravelli and A. Martini, “Juvenile idiopathic arthritis,” The Lancet, vol. 369, no. 9563, pp. 767–778, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. R. P. Donn, J. H. Barrett, A. Farhan et al., “Cytokine gene polymorphisms and susceptibility to juvenile idiopathic arthritis,” Arthritis and Rheumatism, vol. 44, no. 4, pp. 802–810, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. A. J. P. Smith and S. E. Humphries, “Cytokine and cytokine receptor gene polymorphisms and their functionality,” Cytokine and Growth Factor Reviews, vol. 20, no. 1, pp. 43–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Bidwell, L. Keen, G. Gallagher et al., “Cytokine gene polymorphism in human disease: on-line databases,” Genes and Immunity, vol. 1, no. 1, pp. 3–19, 1999. View at Google Scholar · View at Scopus
  8. L. Lepore, M. Pennesi, S. Saletta, S. Perticarari, G. Presani, and M. Prodan, “Study of IL-2, IL-6, TNFα, IFNγ and β in the serum and synovial fluid of patients with juvenile chronic arthritis,” Clinical and Experimental Rheumatology, vol. 12, no. 5, pp. 561–565, 1994. View at Google Scholar · View at Scopus
  9. H. Mangge, H. Kenzian, S. Gallistl et al., “Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes,” Arthritis and Rheumatism, vol. 38, no. 2, pp. 211–220, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Kutukculer, S. Caglayan, and F. Aydogdu, “Study of pro-inflammatory (TNF-α, IL-1α, IL-6) and T-cell-derived (IL- 2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters,” Clinical Rheumatology, vol. 17, no. 4, pp. 288–292, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Field, “Tumour necrosis factor polymorphisms in rheumatic diseases,” QJM, vol. 94, no. 5, pp. 237–246, 2001. View at Google Scholar · View at Scopus
  12. A. H. Hajeer and I. V. Hutchinson, “TNF-α gene polymorphism: clinical and biological implications,” Microscopy Research and Technique, vol. 50, no. 3, pp. 216–228, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Zeggini, W. Thomson, D. Kwiatkowski et al., “Linkage and association studies of single-nucleotide polymorphism-tagged tumor necrosis factor haplotypes in juvenile oligoarthritis,” Arthritis and Rheumatism, vol. 46, no. 12, pp. 3304–3311, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Schmeling, U. Wagner, A. Peterson, and G. Horneff, “Tumor necrosis factor alpha promoter polymorphisms in patients with juvenile idiopathic arthritis,” Clinical and Experimental Rheumatology, vol. 24, no. 1, pp. 103–108, 2006. View at Google Scholar · View at Scopus
  15. B. M. N. Brinkman, T. W. J. Huizinga, S. S. Kurban et al., “Tumour necrosis factor α gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease?” British Journal of Rheumatology, vol. 36, no. 5, pp. 516–521, 1997. View at Google Scholar · View at Scopus
  16. A. S. Low, M. A. Gonzalez-Gay, M. Akil et al., “TNF+489 polymorphism does not contribute to susceptibility to rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 20, no. 6, pp. 829–832, 2002. View at Google Scholar · View at Scopus
  17. K. Hayward and C. A. Wallace, “Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis,” Arthritis Research and Therapy, vol. 11, no. 1, article 216, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. D. J. Lovell, E. H. Giannini, A. Reiff et al., “Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial,” Arthritis and Rheumatism, vol. 48, no. 1, pp. 218–226, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. C. L. Verweij, “Tumour necrosis factor gene polymorphisms as severity markers in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 58, supplement 1, pp. I20–I26, 1999. View at Google Scholar · View at Scopus
  20. J. R. Maxwel, C. Potter, K. L. Hyrich et al., “Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis,” Human Molecular Genetics, vol. 17, no. 22, pp. 3532–3538, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Liu, F. Batliwalla, W. Li et al., “Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis,” Molecular Medicine, vol. 14, no. 9-10, pp. 575–581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Gambhir, A. Lawrence, A. Aggarwal, R. Misra, S. K. Mandal, and S. Naik, “Association of tumor necrosis factor alpha and IL-10 promoter polymorphisms with rheumatoid arthritis in North Indian population,” Rheumatology International, vol. 30, no. 9, pp. 1211–1217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Miterski, S. Drynda, G. Böschow et al., “Complex genetic predisposition in adult and juvenile rheumatoid arthritis,” BMC Genetics, vol. 5, article 2, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. R. E. Petty, T. R. Southwood, P. Manners et al., “International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001,” Journal of Rheumatology, vol. 31, no. 2, pp. 390–392, 2004. View at Google Scholar · View at Scopus
  25. R. C. Lawrence, C. G. Helmick, F. C. Arnett et al., “Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States,” Arthritis and Rheumatism, vol. 41, no. 5, pp. 778–799, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Prahalad and D. N. Glass, “A comprehensive review of the genetics of juvenile idiopathic arthritis,” Pediatric Rheumatology, vol. 6, article 11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Ozen, L. B. Tucker, and L. C. Miller, “Identification of Th subsets in juvenile rheumatoid arthritis confirmed by intracellular cytokine staining,” Journal of Rheumatology, vol. 25, no. 8, pp. 1651–1653, 1998. View at Google Scholar · View at Scopus
  28. M. Gattorno, P. Facchetti, F. Ghiotto et al., “Synovial fluid T cell clones from oligoarticular juvenile arthritis patients display a prevalent Th1/Th0-type pattern of cytokine secretion irrespective of immunophenotype,” Clinical and Experimental Immunology, vol. 109, no. 1, pp. 4–11, 1997. View at Google Scholar · View at Scopus
  29. S. Prahalad, “Genetic analysis of juvenile rheumatoid arthritis: approaches to complex traits,” Current Problems in Pediatric and Adolescent Health Care, vol. 36, no. 3, pp. 83–90, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. W. Thomson and R. Donn, “Juvenile idiopathic arthritis genetics - What's new? What's next?” Arthritis Research, vol. 4, no. 5, pp. 302–306, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Ploski, O. Vinje, K. S. Ronningen et al., “HLA class II alleles and heterogeneity of juvenile rheumatoid arthritis: DRB1*0101 may define a novel subset of the disease,” Arthritis and Rheumatism, vol. 36, no. 4, pp. 465–472, 1993. View at Google Scholar · View at Scopus
  32. Y. Date, N. Seki, S. Kamizono et al., “Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5-flanking region of the TNFα gene and HLA genes,” Arthritis and Rheumatism, vol. 42, no. 12, pp. 2577–2582, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. P. Woo and R. A. Colbert, “An overview of genetics of paediatric rheumatic diseases,” Best Practice and Research, vol. 23, no. 5, pp. 589–597, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. M. B. Moroldo, P. Donnelly, J. Saunders, D. N. Glass, and E. H. Giannini, “Transmission disequilibrium as a test of linkage and association between HLA alleles and pauciarticular-onset juvenile rheumatoid arthritis,” Arthritis and Rheumatism, vol. 41, no. 9, pp. 1620–1624, 1998. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Oen, P. N. Malleson, D. A. Cabral et al., “Cytokine genotypes correlate with pain and radiologically defined joint damage in patients with juvenile rheumatoid arthritis,” Rheumatology, vol. 44, no. 9, pp. 1115–1121, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. A. F. Mourão, J. Caetano-Lopes, P. Costa et al., “Tumor necrosis factor-α -308 genotypes influence inflammatory activity and TNF-α serum concentrations in children with juvenile idiopathic arthritis,” Journal of Rheumatology, vol. 36, no. 4, pp. 837–842, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. M. M. Elahi, K. Asotra, B. M. Matata, and S. S. Mastana, “Tumor necrosis factor alpha—308 gene locus promoter polymorphism: an analysis of association with health and disease,” Biochimica et Biophysica Acta, vol. 1792, no. 3, pp. 163–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. J. C. Aguillón, A. Escobar, V. Ferreira et al., “Daily production of human tumor necrosis factor in LPS-stimulated ex vivo blood culture assays,” European Cytokine Network, vol. 12, no. 1, pp. 105–110, 2001. View at Google Scholar · View at Scopus
  39. G. Kollias, E. Douni, G. Kassiotis, and D. Kontoyiannis, “The function of tumour necrosis factor and receptors in models of multi- organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease,” Annals of the Rheumatic Diseases, vol. 58, supplement 1, pp. I32–I39, 1999. View at Google Scholar · View at Scopus
  40. J. R. Bradley, “TNF-mediated inflammatory disease,” Journal of Pathology, vol. 214, no. 2, pp. 149–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. J. A. J. Barbara, X. Van Ostade, and A. F. Lopez, “Tumour necrosis factor-alpha (TNF-α): the good, the bad and potentially very effective,” Immunology and Cell Biology, vol. 74, no. 5, pp. 434–443, 1996. View at Google Scholar · View at Scopus
  42. J. C. Aguillón, A. Cruzat, O. Aravena, L. Salazar, C. Llanos, and M. Cuchacovich, “Could single-nucleotide polymorphisms (SNPs) affecting the tumour necrosis factor promoter be considered as part of rheumatoid arthritis evolution?” Immunobiology, vol. 211, no. 1-2, pp. 75–84, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Jiménez-Morales, R. Velázquez-Cruz, J. Ramírez-Bello et al., “Tumor necrosis factor-α is a common genetic risk factor for asthma, juvenile rheumatoid arthritis, and systemic lupus erythematosus in a Mexican pediatric population,” Human Immunology, vol. 70, no. 4, pp. 251–256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. C. O. Jacob, F. Hwang, G. D. Lewis, and A. M. Stall, “Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: implications for genetic predisposition and immune regulation,” Cytokine, vol. 3, no. 6, pp. 551–561, 1991. View at Google Scholar · View at Scopus
  45. G. Bouma, J. B. A. Crusius, M. Oudkerk Pool et al., “Secretion of tumour necrosis factor α and lymphotoxin α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease,” Scandinavian Journal of Immunology, vol. 43, no. 4, pp. 456–463, 1996. View at Google Scholar · View at Scopus
  46. L. A. Tartaglia, R. F. Weber, I. S. Figari, C. Reynolds, M. A. Palladino, and D. V. Goeddel, “The two different receptors for tumor necrosis factor mediate distinct cellular responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 20, pp. 9292–9296, 1991. View at Google Scholar · View at Scopus
  47. M. F. McDermott, “Autosomal dominant recurrent fevers. Clinical and genetic aspects,” Revue du Rhumatisme, vol. 66, no. 10, pp. 484–491, 1999. View at Google Scholar · View at Scopus
  48. D. R. Spriggs, S. Deutsch, and D. W. Kufe, “Genomic structure, induction, and production of TNF-alpha,” Immunology series, vol. 56, pp. 3–34, 1992. View at Google Scholar · View at Scopus
  49. M. C. Warlé, A. Farhan, H. J. Metselaar et al., “Are cytokine gene polymorphisms related to in vitro cytokine production profiles?” Liver Transplantation, vol. 9, no. 2, pp. 170–181, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. A. G. Wilson, J. A. Symons, T. L. Mcdowell, H. O. Mcdevitt, and G. W. Duff, “Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 7, pp. 3195–3199, 1997. View at Publisher · View at Google Scholar · View at Scopus
  51. J. P. Bayley, T. H. M. Ottenhoff, and C. L. Verweij, “Is there a future for TNF promoter polymorphisms?” Genes and Immunity, vol. 5, no. 5, pp. 315–329, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. J. P. Mira, A. Cariou, F. Grall et al., “Association of TNF2, a TNF-α promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study,” JAMA, vol. 282, no. 6, pp. 561–568, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. J. P. Bayley, H. De Rooij, P. J. Van Den Elsen, T. W. J. Huizinga, and C. L. Verweij, “Functional analysis of linker-scan mutants spanning the -376, -308, -244, and -238 polymorphic sites of the TNF-α promoter,” Cytokine, vol. 14, no. 6, pp. 316–323, 2001. View at Publisher · View at Google Scholar · View at Scopus
  54. B. M. N. Brinkman, D. Zuijdgeest, E. L. Kaijzel, F. C. Breedveld, and C. L. Verweij, “Relevance of the tumor necrosis factor alpha (TNFα) -308 promoter polymorphism in TNFα gene regulation,” Journal of Inflammation, vol. 46, no. 1, pp. 32–41, 1996. View at Google Scholar · View at Scopus
  55. K. M. Kroeger, K. S. Carville, and L. J. Abraham, “The -308 tumor necrosis factor-α promoter polymorphism effects transcription,” Molecular Immunology, vol. 34, no. 5, pp. 391–399, 1997. View at Publisher · View at Google Scholar · View at Scopus
  56. L. J. Abraham and K. M. Kroeger, “Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease,” Journal of Leukocyte Biology, vol. 66, no. 4, pp. 562–566, 1999. View at Google Scholar · View at Scopus
  57. E. L. Kaijzel, J. P. Bayley, M. V. Van Krugten et al., “Allele-specific quantification of tumor necrosis factor α (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals,” Genes and Immunity, vol. 2, no. 3, pp. 135–144, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Louis, D. Franchimont, A. Piron et al., “Tumour necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans,” Clinical and Experimental Immunology, vol. 113, no. 3, pp. 401–406, 1998. View at Publisher · View at Google Scholar · View at Scopus
  59. T. W. J. Huizinga, R. G. J. Westendorp, E. L. E. M. Bollen et al., “TNF-α promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients,” Journal of Neuroimmunology, vol. 72, no. 2, pp. 149–153, 1997. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Kubota, D. M. McNamara, J. J. Wang et al., “Effects of tumor necrosis factor gene polymorphisms on patients with congestive heart failure,” Circulation, vol. 97, no. 25, pp. 2499–2501, 1998. View at Google Scholar · View at Scopus
  61. C. L. W. Fong, A. H. Siddiqui, and D. F. Mark, “Identification and characterization of a novel repressor site in the human tumor necrosis factor α gene,” Nucleic Acids Research, vol. 22, no. 6, pp. 1108–1114, 1994. View at Google Scholar · View at Scopus
  62. F. Pociot, S. D'Alfonso, S. Compasso, R. Scorza, and P. M. Richiardi, “Functional analysis of a new polymorphism in the human TNF α gene promoter,” Scandinavian Journal of Immunology, vol. 42, no. 4, pp. 501–504, 1995. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Ozen, M. Alikasifoglu, A. Bakkaloglu et al., “Tumour necrosis factor α G → A -238 and G → A -308 polymorphisms in juvenile idiopathic arthritis,” Rheumatology, vol. 41, no. 2, pp. 223–227, 2002. View at Google Scholar · View at Scopus
  64. B. J. Scallon, M. A. Moore, H. Trinh, D. M. Knight, and J. Ghrayeb, “Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions,” Cytokine, vol. 7, no. 3, pp. 251–259, 1995. View at Publisher · View at Google Scholar · View at Scopus
  65. J. C. Knight, I. Udalova, A. V. S. Hill et al., “A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria,” Nature Genetics, vol. 22, no. 2, pp. 145–150, 1999. View at Publisher · View at Google Scholar · View at Scopus
  66. J. C. Knight, B. J. Keating, K. A. Rockett, and D. P. Kwiatkowski, “In vivo characterization of regulatory polymorphisms by allele-specific quantification of RNA polymerase loading,” Nature Genetics, vol. 33, no. 4, pp. 469–475, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. D. M. Butler, R. N. Maini, M. Feldmann, and F. M. Brennan, “Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-α antibody with the interleukin-1 receptor antagonist,” European Cytokine Network, vol. 6, no. 4, pp. 225–230, 1995. View at Google Scholar · View at Scopus
  68. M. Feldmann, F. M. Brennan, and R. N. Maini, “Role of cytokines in rheumatoid arthritis,” Annual Review of Immunology, vol. 14, pp. 397–440, 1996. View at Publisher · View at Google Scholar · View at Scopus
  69. J. Cuenca, M. Cuchacovich, C. Pérez et al., “The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis,” Rheumatology, vol. 42, no. 2, pp. 308–313, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Keffer, L. Probert, H. Cazlaris et al., “Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis,” The EMBO Journal, vol. 10, no. 13, pp. 4025–4031, 1991. View at Google Scholar · View at Scopus
  71. M. J. Elliott, R. N. Maini, M. Feldmann et al., “Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α,” Arthritis and Rheumatism, vol. 36, no. 12, pp. 1681–1690, 1993. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Kempeni, “Preliminary results of early clinical trials with the fully human anti- TNFα monoclonal antibody D2E7,” Annals of the Rheumatic Diseases, vol. 58, supplement 1, pp. I70–I72, 1999. View at Google Scholar · View at Scopus
  73. M. E. Weinblatt, “The role of current strategies in the future treatment of rheumatoid arthritis,” Rheumatology, vol. 38, no. 2, pp. 19–23, 1999. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Modesto, A. Patiño-García, E. Sotillo-Piñeiro et al., “TNF-α promoter gene polymorphisms in Spanish children with persistent oligoarticular and systemic-onset juvenile idiopathic arthritis,” Scandinavian Journal of Rheumatology, vol. 34, no. 6, pp. 451–454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Hohler, A. Kruger, P. M. Schneider et al., “A TNF-α promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis,” Journal of Investigative Dermatology, vol. 109, no. 4, pp. 562–565, 1997. View at Google Scholar · View at Scopus
  76. A. Martínez, M. Fernández-Arquero, D. Pascual-Salcedo et al., “Primary association of tumor necrosis factor-region genetic markers with susceptibility to rheumatoid arthritis,” Arthritis and Rheumatism, vol. 43, no. 6, pp. 1366–1370, 2000. View at Publisher · View at Google Scholar · View at Scopus
  77. D. Khanna, H. Wu, G. Park et al., “Association of tumor necrosis factor α polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort,” Arthritis and Rheumatism, vol. 54, no. 4, pp. 1105–1116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. J. E. Fonseca, J. Cavaleiro, J. Teles et al., “Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter,” Arthritis Research and Therapy, vol. 9, article R37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. O. M. Popa, M. Bojinca, V. Bojinca et al., “A pilot study of the association of tumor necrosis factor alpha polymorphisms with psoriatic arthritis in the Romanian population,” International Journal of Molecular Sciences, vol. 12, no. 8, pp. 5052–5059, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Giardina, U. Hüffmeier, J. Ravindran et al., “Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus,” Arthritis and Rheumatism, vol. 63, no. 12, pp. 3801–3806, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. M. V. Van Krugten, T. W. J. Huizinga, E. L. Kaijzel et al., “Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis,” Genes and Immunity, vol. 1, no. 2, pp. 91–96, 1999. View at Google Scholar · View at Scopus
  82. W. M. Kooloos, J. A. M. Wessels, S. M. Van Der Kooij, C. F. Allaart, T. W. J. Huizinga, and H. J. Guchelaar, “Optimalisation of the clinical pharmacogenetic model to predict methotrexate treatment response: the influence of the number of haplotypes of MTHFR 1298A-677C alleles on probability to respond,” Annals of the Rheumatic Diseases, vol. 68, no. 8, article 1371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. D. Plant, J. Bowes, C. Potter et al., “Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci,” Arthritis and Rheumatism, vol. 63, no. 3, pp. 645–653, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. L. Breda, M. Del Torto, S. De Sanctis, and F. Chiarelli, “Biologics in children's autoimmune disorders: efficacy and safety,” European Journal of Pediatrics, vol. 170, no. 2, pp. 157–167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. L. Padyukov, J. Lampa, M. Heimbürger et al., “Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 62, no. 6, pp. 526–529, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Schmeling and G. Horneff, “Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis,” Rheumatology International, vol. 27, no. 4, pp. 383–386, 2007. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Cimaz, M. A. Cazalis, C. Reynaud et al., “IL1 and TNF gene polymorphisms in patients with juvenile idiopathic arthritis treated with TNF inhibitors,” Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 900–904, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Basic, D. Pavlovic, T. Jevtovic-Stoimenov et al., “Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-α-308GG genotype,” Journal of Physiology and Biochemistry, vol. 66, no. 2, pp. 173–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Ongaro, M. De Mattei, A. Pellati et al., “Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFα therapy in rheumatoid arthritis?” Rheumatology International, vol. 28, no. 9, pp. 901–908, 2008. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Guis, N. Balandraud, J. Bouvenot et al., “Influence of -308 A/G polymorphism in the tumor necrosis factor α gene on etanercept treatment in rheumatoid arthritis,” Arthritis Care & Research, vol. 57, no. 8, pp. 1426–1430, 2007. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Seitz, U. Wirthmüller, B. Möller, and P. M. Villiger, “The -308 tumour necrosis factor-α gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients,” Rheumatology, vol. 46, no. 1, pp. 93–96, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. D. D. O'Rielly, N. M. Roslin, J. Beyene, A. Pope, and P. Rahman, “TNF-α—308 G/A polymorphism and responsiveness to TNF-α blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis,” Pharmacogenomics Journal, vol. 9, no. 3, pp. 161–167, 2009. View at Publisher · View at Google Scholar · View at Scopus
  93. C. P. Kang, K. W. Lee, D. H. Yoo, C. Kang, and S. C. Bae, “The influence of a polymorphism at position -857 of the tumour necrosis factor α gene on clinical response to etanercept therapy in rheumatoid arthritis,” Rheumatology, vol. 44, no. 4, pp. 547–552, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. B. Mugnier, J. Roudier, A. Martinez et al., “Tumor necrosis factor α haplotypes versus tumor necrosis factor α -308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 50, no. 12, pp. 4075–4077, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. A. Balog, G. Klausz, J. Gál et al., “Investigation of the prognostic value of TNF-α gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-α production and apoptosis,” Pathobiology, vol. 71, no. 5, pp. 274–280, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. J. E. Fonseca, T. Carvalho, M. Cruz et al., “Polymorphism at position -308 of the tumour factor α gene and rheumatoid arthritis pharmacogenetics,” Annals of the Rheumatic Diseases, vol. 64, no. 5, pp. 793–794, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. H. Lee, J. D. Ji, S. C. Bae, and G. G. Song, “Associations between tumor necrosis factor-α (TNF-α) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-α blockers in rheumatoid arthritis: a metaanalysis update,” Journal of Rheumatology, vol. 37, no. 4, pp. 740–746, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Chatzikyriakidou, I. Georgiou, P. V. Voulgari, A. I. Venetsanopoulou, and A. A. Drosos, “Combined tumour necrosis factor-α and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-α therapy and explain controversies of studies based on a single polymorphism,” Rheumatology, vol. 46, no. 6, pp. 1034–1035, 2007. View at Publisher · View at Google Scholar · View at Scopus
  99. J. A. Pinto, I. Rego, C. Fernandez-López et al., “Polymorphisms in genes encoding tumor necrosis factor-α and HLA-DRB1 are not associated with response to infliximab in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 35, no. 1, pp. 177–178, 2008. View at Google Scholar · View at Scopus
  100. S. Pavy, E. J. M. Toonen, C. Miceli-Richard et al., “Tumour necrosis factor α-308G→A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis,” Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 1022–1028, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Suarez-Gestal, E. Perez-Pampin, M. Calaza, J. J. Gomez-Reino, and A. Gonzalez, “Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study,” Arthritis Research and Therapy, vol. 12, no. 2, article R72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. H. Marotte, B. Arnaud, J. Diasparra, S. Zrioual, and P. Miossec, “Association between the level of circulating bioactive tumor necrosis factor α and the tumor necrosis factor α gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor α inhibitor,” Arthritis and Rheumatism, vol. 58, no. 5, pp. 1258–1263, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. C. Miceli-Richard, E. Comets, C. Verstuyft et al., “A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 67, no. 4, pp. 478–484, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. P. Diak, J. Siegel, L. La Grenade, L. Choi, S. Lemery, and A. McMahon, “Tumor necrosis factor α blockers and malignancy in children: forty-eight cases reported to the food and drug administration,” Arthritis and Rheumatism, vol. 62, no. 8, pp. 2517–2524, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. G. Horneff, I. Foeldvari, K. Minden, D. Moebius, and T. Hospach, “Report on malignancies in the German juvenile idiopathic arthritis registry,” Rheumatology, vol. 50, no. 1, pp. 230–236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. G. Horneff, T. Hospach, G. Dannecker et al., “Updated statement by the German Society for Pediatric and Adolescent Rheumatology (GKJR) on the FDA's report regarding malignancies in anti-TNF-treated patients from Aug. 4, 2009,” Zeitschrift fur Rheumatologie, vol. 69, no. 6, pp. 561–567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. P. McCroskery, C. A. Wallace, D. J. Lovell et al., “Summary of worldwide pediatric malignancies reported after exposure to etanercept,” Pediatric Rheumatology, vol. 8, article 18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Harrison, B. Nordstom, Y. Gu, C. Mercaldi, P. Aquino, and D. Mines, “Risk of malignancy in biologics-naive juvenile arthritis patients,” Annals of the Rheumatic Diseases, no. 3, article 631, 2010. View at Google Scholar
  109. J. F. Simard, M. Neovius, S. Hagelberg, and J. Askling, “Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study.,” Annals of the Rheumatic Diseases, no. 3, article 81, 2010. View at Google Scholar
  110. T. Beukelman, F. Xie, L. Chen et al., “Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment,” Arthritis and Rheumatism, vol. 64, no. 8, pp. 2773–2780, 2012. View at Publisher · View at Google Scholar · View at Scopus
  111. B. L. Nordstrom, D. Mines, Y. Gu, C. Mercaldi, P. Aquino, and M. J. Harrison, “Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologics,” Arthritis Care & Research. In press.
  112. F. Wolfe and K. Michaud, “Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients,” Arthritis and Rheumatism, vol. 50, no. 6, pp. 1740–1751, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. F. Wolfe and K. Michaud, “The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation,” Arthritis and Rheumatism, vol. 56, no. 5, pp. 1433–1439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  114. J. P. Leombruno, T. R. Einarson, and E. C. Keystone, “The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events,” Annals of the Rheumatic Diseases, vol. 68, no. 7, pp. 1136–1145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  115. E. Dommasch and J. M. Gelfand, “Is there truly a risk of lymphoma from biologic therapies?” Dermatologic Therapy, vol. 22, no. 5, pp. 418–430, 2009. View at Publisher · View at Google Scholar · View at Scopus
  116. F. B. Pallavicini, R. Caporali, P. Sarzi-Puttini et al., “Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry,” Autoimmunity Reviews, vol. 9, no. 3, pp. 175–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. J. Franklin, M. Lunt, D. Bunn, D. Symmons, and A. Silman, “Incidence of lymphoma in a large primary care derived cohort or cases of inflammatory polyarthritis,” Annals of the Rheumatic Diseases, vol. 65, no. 5, pp. 617–622, 2006. View at Publisher · View at Google Scholar · View at Scopus
  118. R. Q. Cron and T. Beukelman, “Guilt by association—what is the true risk of malignancy in children treated with etanercept for JIA?” Pediatric Rheumatology, vol. 8, article 23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. P. Raaschou, J. F. Simard, M. Neovius, and J. Askling, “Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis?: a national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents,” Arthritis and Rheumatism, vol. 63, no. 7, pp. 1812–1822, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. F. Balkwill, “Tumor necrosis factor or tumor promoting factor?” Cytokine and Growth Factor Reviews, vol. 13, no. 2, pp. 135–141, 2002. View at Publisher · View at Google Scholar · View at Scopus
  121. A. Ferrajoli, M. J. Keating, T. Manshouri et al., “The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia,” Blood, vol. 100, no. 4, pp. 1215–1219, 2002. View at Google Scholar · View at Scopus
  122. R. Y. Liu, C. Fan, G. Liu, N. E. Olashaw, and K. S. Zuckerman, “Activation of p38 mitogen activated protein is required for tumor Necrosis factor-α-supported proliferation of leukemia and lymphoma cell lines,” The Journal of Biological Chemistry, vol. 275, no. 28, pp. 21086–21095, 2000. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Jaiswal, N. F. LaRusso, L. J. Burgart, and G. J. Gores, “Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism,” Cancer Research, vol. 60, no. 1, pp. 184–190, 2000. View at Google Scholar · View at Scopus
  124. L. B. Nabors, E. Suswam, Y. Huang, X. Yang, M. J. Johnson, and P. H. King, “Tumor necrosis factor α induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR,” Cancer Research, vol. 63, no. 14, pp. 4181–4187, 2003. View at Google Scholar · View at Scopus
  125. V. A. Polunovsky, C. H. Wendt, D. H. Ingbar, M. S. Peterson, and P. B. Bitterman, “Induction of endothelial cell apoptosis by TNFα: modulation by inhibitors of protein synthesis,” Experimental Cell Research, vol. 214, no. 2, pp. 584–594, 1994. View at Publisher · View at Google Scholar · View at Scopus
  126. L. F. Fajardo, H. H. Kwan, J. Kowalski, S. D. Prionas, and A. C. Allison, “Dual role of tumor necrosis factor-α in angiogenesis,” American Journal of Pathology, vol. 140, no. 3, pp. 539–544, 1992. View at Google Scholar · View at Scopus
  127. E. R. Manusama, P. T. G. A. Nooijen, J. Stavast, N. M. C. Durante, R. L. Marquet, and A. M. M. Eggermont, “Synergistic antitumour effect of recombinant human tumour necrosis factor α with melphalan in isolated limb perfusion in the rat,” British Journal of Surgery, vol. 83, no. 4, pp. 551–555, 1996. View at Publisher · View at Google Scholar · View at Scopus
  128. A. L. B. Seynhaeve, J. H. W. De Wilt, S. T. Van Tiel, A. M. M. Eggermont, and T. L. M. Ten Hagen, “Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity,” British Journal of Cancer, vol. 86, no. 7, pp. 1174–1179, 2002. View at Google Scholar · View at Scopus
  129. H. P. Marsh, N. A. Haldar, M. Bunce et al., “Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation,” British Journal of Cancer, vol. 89, no. 6, pp. 1096–1101, 2003. View at Publisher · View at Google Scholar · View at Scopus
  130. K. Nakajima, M. Sasaki, D. Nojima et al., “Tumor necrosis factor-α gene mutations and genotype changes in renal cell carcinoma,” Journal of Urology, vol. 165, no. 2, pp. 612–615, 2001. View at Publisher · View at Google Scholar · View at Scopus
  131. B. R. Oh, M. Sasaki, G. Perinchery et al., “Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-α (TNF-α) gene in patients with prostate cancer,” Journal of Urology, vol. 163, no. 5, pp. 1584–1587, 2000. View at Google Scholar · View at Scopus
  132. K. Tsukasaki, C. W. Miller, T. Kubota et al., “Tumor necrosis factor α polymorphism associated with increased susceptibility to development of adult T-cell leukemia/lymphoma in human T-lymphotropic virus type 1 carriers,” Cancer Research, vol. 61, no. 9, pp. 3770–3774, 2001. View at Google Scholar · View at Scopus
  133. S. Mestiri, N. Bouaouina, S. B. Ahmed et al., “Genetic variation in the tumor necrosis factor-α promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma,” Cancer, vol. 91, no. 4, pp. 672–678, 2001. View at Publisher · View at Google Scholar · View at Scopus
  134. J. E. Jeng, J. F. Tsai, L. Y. Chuang et al., “Tumor necrosis factor-α 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma,” Neoplasia, vol. 9, no. 11, pp. 987–992, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. J. C. Machado, C. Figueiredo, P. Canedo et al., “A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma,” Gastroenterology, vol. 125, no. 2, pp. 364–371, 2003. View at Publisher · View at Google Scholar · View at Scopus
  136. S. Y. Ho, Y. J. Wang, H. L. Chen et al., “Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-α promoter gene,” Cancer Causes and Control, vol. 15, no. 7, pp. 657–663, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. K. Seidemann, M. Zimmermann, M. Book et al., “Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: results from Berlin-Frankfurt-Münster Trial NHL-BFM 95,” Journal of Clinical Oncology, vol. 23, no. 33, pp. 8414–8421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  138. Y. H. Lee, J. D. Ji, and G. G. Song, “Tumor necrosis factor-α promoter -308 A/G polymorphism and rheumatoid arthritis susceptibility: a metaanalysis,” Journal of Rheumatology, vol. 34, no. 1, pp. 43–49, 2007. View at Google Scholar · View at Scopus
  139. G. Mamyrova, T. P. O'Hanlon, L. Sillers et al., “Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis,” Arthritis and Rheumatism, vol. 58, no. 12, pp. 3941–3950, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. H. Chinoy, F. Salway, S. John et al., “Tumour necrosis factor-α single nucleotide polymorphisms are not independent of HLA class I in UK Caucasians with adult onset idiopathic inflammatory myopathies,” Rheumatology, vol. 46, no. 9, pp. 1411–1416, 2007. View at Publisher · View at Google Scholar · View at Scopus
  141. L. R. Ferguson, D. Y. Han, C. Huebner et al., “Tumor necrosis factor receptor superfamily, member 1B haplotypes increase or decrease the risk of inflammatory bowel diseases in a New Zealand caucasian population,” Gastroenterology Research and Practice, vol. 2009, Article ID 591704, 9 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. J. Sýkora, I. Šubrt, P. Dědek et al., “Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G→A and pediatric inflammatory bowel disease: implications in ulcerative colitis and crohn's disease,” Journal of Pediatric Gastroenterology and Nutrition, vol. 42, no. 5, pp. 479–487, 2006. View at Publisher · View at Google Scholar · View at Scopus